PARP Inhibition for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presentation – Kim Chi

Kim Chi presented an update on the utilization of PARP inhibitors during the Management of Castration-Resistant Prostate Cancer (CRPC) session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Leading his presentation with the most recent positive phase III results from Lynparza® (olaparib), the only PARP inhibitor with positive phase III results in four different cancer types….

Read the full article here

Related Articles